Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers
Human epidermal growth factor receptor 2 (ErbB2/HER2) is a tyrosine kinase receptor that is overexpressed in 25% of primary human breast cancers, as well as in multiple other cancers. HER2‐targeted therapies improved progression‐free and overall survival in patients with HER2+ breast cancers. Howeve...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13419 |